Segment Information - Schedule of Financial Information by Segment (Details) - USD ($)	3 Months Ended				12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Net revenues					$ 22,771,000	$ 17,975,000
Gross profit					6,755,000	(1,690,000)
Direct expenses					81,041,000	144,198,000
Segment contribution					(74,286,000)	(145,888,000)
Indirect expenses					118,001,000	(120,288,000)
Loss from operations					(192,287,000)	(25,600,000)
Components of other
Change in fair value of contingent consideration liability					(104,339,000)	(126,277,000)
Change in fair value of contingent stock consideration					(159,000)	186,000
Goodwill impairment	$ 82,714,000	$ 0	$ 29,633,000	$ 3,610,000	112,347,000	3,610,000
IPR&D impairment					107,800,000	0
Cell Therapy
Segment Reporting Information [Line Items]
Direct expenses					28,694,000	75,379,000
Segment contribution					(28,694,000)	(75,379,000)
Components of other
Goodwill impairment					112,347,000
Biobanking
Segment Reporting Information [Line Items]
Net revenues					5,441,000	5,512,000
Gross profit					3,791,000	1,976,000
Direct expenses					1,752,000	1,699,000
Segment contribution					2,039,000	277,000
Degenerative Disease
Segment Reporting Information [Line Items]
Net revenues					17,330,000	12,463,000
Gross profit					2,964,000	(3,666,000)
Direct expenses					9,720,000	10,859,000
Segment contribution					(6,756,000)	(14,525,000)
Components of other
Goodwill impairment						3,610,000
Other
Segment Reporting Information [Line Items]
Direct expenses					40,876,000	56,261,000
Segment contribution					(40,876,000)	(56,261,000)
Indirect expenses					118,001,000	(120,288,000)
Components of other
Change in fair value of contingent consideration liability					(104,339,000)	(126,277,000)
Change in fair value of contingent stock consideration						186,000
IPR&D impairment					107,800,000
Amortization					2,193,000	2,193,000
Total other					$ 118,001,000	$ (120,288,000)